TICKERNERD
Menu
QNTMQNTMHealthcare · Biotechnology

QNTM Stock Forecast: Quantum BioPharma Ltd. Price Predictions for 2026-2027

Last close, 7 Oct 2026
$3.15
+1.78% on the day

The 1 Wall Street analysts covering Quantum BioPharma Ltd. hold a median 12-month price target of $12 — +288.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 50 of 100 as at 6 Oct 2026 — in the upper half.

Market cap
$21.0M
Ticker Nerd rank
50 / 100
Median analyst target
$12
Analysts covering
1
Revenue$0.0
Operating income−$2.3M
Net income−$3.1M
Free cash flow−$1.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−12.6%
1M
−2.9%
YTD
−56.9%
1Y
−81.7%
From 52W high
−81.7%
From 52W low
+49.8%
$2
$17
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

QNTM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Quantum BioPharma Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 6 Oct 2026
50 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Issuance
87
Size
87
Growth
85
Accruals
80
Volatility
66
Revisions
25
Value
25
Quality
20
Momentum
13

Issuance (87): The share count has been shrinking and the company is not leaning on new borrowing.

Momentum (13): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

QNTM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on QNTM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20Jan 26Apr 26Jul 26Oct 26QNTMHigh $12Median $12Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $12Median $12High $12

The green dot is the last close — the median target sits +288.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
31 Aug 2026Rodman & RenshawInitiatesBuy$8.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. QNTM appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

QNTM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 7 Oct 2026, Quantum BioPharma Ltd. returned −81.7% against +17.4% for the S&P 500, dividends included.

QNTM vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26QNTMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

QNTM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Quantum BioPharma Ltd. (QNTM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.4×

Cheaper than 80% of US stocks

Price / sales
—
Price / book
3.1×

Cheaper than 31% of US stocks

EV / EBITDA
−1.8×

Cheaper than 71% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−621.5%

Higher than 2% of US stocks

Return on assets
−51.8%

Higher than 7% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Quantum BioPharma Ltd. (QNTM) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Quantum BioPharma Ltd. has a market value of $21.0M and an enterprise value of $21.7M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$25.3M.

  • Free cash flow in the twelve months to 30 June 2026: −$5.5M.

  • Shares outstanding: 7.6M.

  • Trailing P/E: −0.4×; forward P/E: −0.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Quantum BioPharma Ltd. employs 17 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 6 Oct 2026

Data provided by Twelve Data

Peers

QNTM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
QNTMQuantum BioPharma Ltd.$21.0M
50
ATOSAtossa Therapeutics, Inc.$24.4M
25
ABVCABVC BioPharma, Inc.$25.9M
12
KYNBKyntra Bio, Inc.$24.1M
42
NXTCNextCure, Inc.$26.0M
78
QNCXQuince Therapeutics, Inc.$26.2M
31
PLRZPolyrizon Ltd.$22.9M
16

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Quantum BioPharma Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest QNTM news & analysis

Quantum BioPharma Signs Contract with Thermo Fisher Scientific's Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis

GlobeNewsWire · 6 Oct 2026positive

Quantum BioPharma has signed a contract with Thermo Fisher Scientific's clinical research business to implement a randomized, double-blind, placebo-controlled Phase 2 study of its neuroprotective therapy, Lucid-MS, in multiple sclerosis.

Why it matters — For Quantum BioPharma watchers, partnering with a leading global contract research organization signals progress and credibility in advancing a key Phase 2 trial for its novel multiple sclerosis candidate.

IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd.

GlobeNewsWire · 30 Sept 2026neutral

IBN announced the release of the latest episode of The BioMedWire Podcast, featuring the return of Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd. The episode is being distributed through IBN's syndication channels.

Why it matters — A QNTM watcher would care because it highlights ongoing communications activity from the company's Executive Co-Chair, which may raise visibility for Quantum BioPharma among the investment community.

Quantum Biopharma Licensee Unbuzzd Wellness to Advance Clinically Validated Alcohol Metabolism Accelerant After Appointing Zappy as CEO

GlobeNewsWire · 24 Sept 2026positive

Quantum BioPharma Ltd.'s licensee Unbuzzd Wellness announced the appointment of Zappy as CEO to advance its clinically validated alcohol metabolism accelerant. The announcement was made in Toronto on Sept. 24, 2026, via GlobeNewsWire.

Why it matters — QNTM watchers would care because progress by its licensee Unbuzzd Wellness on its alcohol metabolism product could reflect on the value of Quantum BioPharma's licensing arrangement and pipeline.

Quantum BioPharma to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto

Newsfile Corp · 15 Sept 2026neutral

Quantum BioPharma Ltd. announced its participation in the 3rd Annual ArcStone-Kingswood Growth Summit, scheduled for September 16, 2026, at the Sheraton Center Toronto Hotel in Toronto. The biopharmaceutical company, which develops drug candidates for neurodegenerative, metabolic, and alcohol misuse disorders, will attend the event.

Why it matters — The announcement signals company exposure at an investor-oriented growth summit, which QNTM watchers may consider relevant for corporate visibility and networking.

FAQ

Frequently asked questions about QNTM stock

What is the QNTM stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Quantum BioPharma Ltd. have a median 12-month price target of $12, with estimates ranging from $12 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is QNTM stock a buy right now?

Of the 1 analysts covering Quantum BioPharma Ltd., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Quantum BioPharma Ltd. 50 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank QNTM?

As at 6 Oct 2026, Quantum BioPharma Ltd. ranks 50 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (87 of 100).

Will QNTM stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +288.7% from the last close, and Ticker Nerd's factor model ranks Quantum BioPharma Ltd. 50 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the QNTM stock forecast for 2030?

No analyst covering Quantum BioPharma Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for QNTM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $12 over the next 12 months.

How has QNTM stock performed over the past year?

Quantum BioPharma Ltd. returned -81.7% over the 12 months to 7 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Quantum BioPharma Ltd. do?

Quantum BioPharma Ltd. Class B Subordinate Voting Shares represents the equity interest in Quantum BioPharma Ltd., a Toronto-based biopharmaceutical company focused on developing and advancing biotech solutions for challenging neurodegenerative, metabolic, inflammatory, and alcohol misuse disorders.

What is the latest news on QNTM?

The most recent item we track (GlobeNewsWire, 6 Oct 2026): "Quantum BioPharma Signs Contract with Thermo Fisher Scientific's Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis". Quantum BioPharma has signed a contract with Thermo Fisher Scientific's clinical research business to implement a randomized, double-blind, placebo-controlled Phase 2 study of its neuroprotective therapy, Lucid-MS, in multiple sclerosis.

Company

About Quantum BioPharma Ltd.

Quantum BioPharma Ltd. Class B Subordinate Voting Shares represents the equity interest in Quantum BioPharma Ltd., a Toronto-based biopharmaceutical company focused on developing and advancing biotech solutions for challenging neurodegenerative, metabolic, inflammatory, and alcohol misuse disorders. The company’s current activities center on a portfolio of drug candidates and related life sciences assets across its biopharmaceutical and strategic investments segments. Its Class B shares provide exposure to a company operating in specialty therapeutics and biomedical innovation, with a structure that includes subordinate voting rights relative to the company’s Class A multiple voting shares. Quantum BioPharma Ltd. serves institutional and retail market participants interested in the life sciences sector, where clinical development, intellectual property, and asset portfolio management are key parts of the business model.

CEO Mr. Zeeshan Saeed · 17 employees · Canada · https://www.quantumbiopharma.com